Loading organizations...
Kupando, based in Schönefeld, Germany, develops TLR 4/7 agonists to stimulate innate and trained immunity for oncology and infectious diseases. Its lead candidate, KUP101, targets advanced solid tumors like skin cancer, with preclinical programs addressing antimicrobial resistance and vaccines. The private biotech company has raised a total of €23 million in Series A funding, including an initial €13 million in 2022 led by Remiges Ventures, and an additional €10 million secured in March 2026. Key investors include Remiges Ventures, LifeCare Partners, Brandenburg Kapital, and High-Tech Gründerfonds, while its board features Chair Jörn Aldag and Kazuhiko Nonomura. This funding supports the Phase 1b trial of KUP101 and advances its preclinical infectious disease programs. Kupando was founded in 2018 by Johanna Holldack.
Kupando has raised $1.3B across 2 funding rounds.
Kupando has raised $1.3B in total across 2 funding rounds.
Kupando has raised $1.3B across 2 funding rounds. Most recently, it raised $11.5M Series A Extension in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 18, 2026 | $11.5M Series A Plus | Lifecare Partners, Kazuhiko Nonomura | Brandenburg Kapital, Martin Raditsch, Phd, Rttp, High Tech Grunderfonds, Ventura BioMed Investors | Announced |
| Sep 26, 2022 | $1.3B Series A | Lifecare Partners, Remiges Ventures | Brandenburg Kapital, High Tech Grunderfonds, Ventura BioMed Investors | Announced |
Kupando has raised $1.3B in total across 2 funding rounds.
Kupando's investors include LifeCare Partners, Kazuhiko NONOMURA, Brandenburg Kapital, Martin Raditsch, PhD, RTTP, High-Tech Grunderfonds, Ventura BioMed Investors, Remiges Ventures.
